| 03.18.24 | Top 10 pharma R&D budgets for ’23; J&J-partnered biotech files latest IPO

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

8 Monate vor

Html
Text


A message from bioduro-sundia

Today’s Big News

Mar 18, 2024

The top 10 pharma R&D budgets for 2023

J&J-allied Contineum files for IPO to take fight to BMS, Roche and more

Chinese biotech's MASH candidate reduces liver fat in phase 2 trial

After calling on Congress to fund women's health, Biden directs agencies to boost R&D


A message from Worldwide Clinical Trials

Featured

The top 10 pharma R&D budgets for 2023

By Gabrielle Masson

After nearly a decade as No. 1, Roche was finally knocked off our list’s top spot, sent spinning down the ladder by a whopping $30 billion from Merck & Co.

J&J-allied Contineum files for IPO to take fight to BMS, Roche and more

By Nick Paul Taylor

The biotech IPO class of 2024 could be getting another member. Contineum Therapeutics is the latest company to test the waters, filing paperwork to raise money for phase 2 clinical trials of its lead prospect and a Johnson & Johnson-partnered molecule.

Chinese biotech's MASH candidate reduces liver fat in phase 2 trial

By Max Bayer

Chipscreen Biosciences' metabolic dysfunction-associated steatohepatitis (MASH) candidate reduced patients' liver fat levels, adding further momentum to drugs aimed at the condition.

After calling on Congress to fund women's health, Biden directs agencies to boost R&D

By Annalee Armstrong

Ten days after asking Congress to fund women’s health research with $12 billion, President Joe Biden is doing what he can to boost investment via an executive order to expand and improve research on women’s health.


A message from Pharma PR & Communications Summit

UPDATED: Despite early death concerns, FDA advisers back J&J and Legend's Carvykti and BMS' Abecma for earlier myeloma

By Angus Liu

Even though the BCMA CAR-T therapies Carvykti and Abecma showed a potential problem of early patient deaths in two separate trials, experts on the FDA’s Oncologic Drugs Advisory Committee still believe that the drugs' long-term benefits outweigh their risks.

Pfizer set to collect roughly $2.6B in selloff of Haleon shares, reducing stake from 32% to 24%

By Kevin Dunleavy

Two months after GSK sold a significant chunk of its stake in Haleon, Pfizer is prepared to do the same with a larger selloff, according to the consumer healthcare company. Pfizer is set to reduce its stake in Haleon from 32% to 24% by selling 630 million shares in a public offering.

Oxford Nanopore taps SeqOne for rare disease DNA diagnostic partnership

By Conor Hale

The goal will be to provide an end-to-end platform that applies extra-long nanopore sequencing reads to whole genomes—initially in order to help identify variants associated with rare diseases, before expanding the project’s scope into cancer testing.

Novartis lays out $256M for antibody plant expansion in Singapore, plots 100 hires

By Fraiser Kansteiner

Novartis broke ground on a $256 million expansion of its biopharmaceutical production facility in Singapore. The project will introduce digitalization and automation at the site in a bid to boost manufacturing productivity and to help upskill the company’s workforce.

Fierce podcasts

Don’t miss an episode

'The Top Line': Inclusivity in psoriasis trials with Takeda

In this episode of 'The Top Line,' Fierce Biotech Senior Editor Annalee Armstrong interviews Karen Correa, Ph.D., from Takeda, discussing the crucial need for pharmaceutical companies to prioritize diversity in clinical trials.

'Podnosis': A deep dive into health plan and health system earnings

'The Top Line': Fierce Medtech's Fierce 15

Whitepaper: Scaling to New Heights: Robust Scale Up from Shake Flask to Commercial AAV Manufacturing for All Patient Populations

This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way,providing a robust and adaptable manufacturing platform for gene therapy breakthroughs.

Resources

Whitepaper

Pediatric Clinical Trials: Considerations for Enrollment and Retention

Explore the nuanced approaches necessary for successful pediatric drug development.

CNS Market Outlook, 2024

This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment.

Presented by Blue Matter, strategic consultants in the life sciences